Impact of seasonal malaria chemoprevention based on the number of medicines doses received on malaria burden among children aged 3–59 months in Nigeria: A propensity score‐matched analysis
Authors: Huang Sikai , Baker Kevin , Ibinaiye Taiwo , Oresanya Olusola , Nnaji Chuks , Richardson Sol 
Published: June 2024

Background

Seasonal malaria chemoprevention using sulfadoxine‐pyrimethamine plus amodiaquine (sulfadoxine‐pyrimethamine plus amodiaquine on Day 1 and amodiaquine on both Day 2 and Day 3) is delivered to children aged 3–59 months in areas of highly season malaria transmission. While the overall population‐level impact of seasonal malaria chemoprevention on malaria control has been documented in various countries and time periods, there is no clear evidence regarding seasonal malaria chemoprevention impact based on the number of medicine doses children receive in one cycle in routine programmatic conditions.

Methods

Data were extracted from Nigeria's routinely collected seasonal malaria chemoprevention end‐of‐round coverage surveys (2021, 2022). We matched seasonal malaria chemoprevention‐targeted children who received specific numbers of seasonal malaria chemoprevention medicines with those who did not receive any doses of seasonal malaria chemoprevention medicines (non‐sulfadoxine‐pyrimethamine plus amodiaquine) using multiple sets of propensity score matches. We performed multilevel logistic regression for each matched group to evaluate the association between the number of doses of seasonal malaria chemoprevention medicines and monthly confirmed malaria cases (caregiver‐reported malaria infection diagnosed by rapid diagnostic test at a health facility following the penultimate cycle of seasonal malaria chemoprevention).

Results

Among 21,621 SMC‐targeted children, 9.7% received non‐sulfadoxine‐pyrimethamine plus amodiaquine, 0.5% received only Day 1 sulfadoxine‐pyrimethamine plus amodiaquine, 1.0% received Day 1 sulfadoxine‐pyrimethamine plus amodiaquine and either Day 2 amodiaquine or Day 3 amodiaquine (sulfadoxine‐pyrimethamine plus amodiaquine + amodiaquine), and 88.8% received Day 1 sulfadoxine‐pyrimethamine plus amodiaquine and both Day 2 and Day 3 amodiaquine (sulfadoxine‐pyrimethamine plus amodiaquine + amodiaquine + amodiaquine). Children receiving only Day 1 sulfadoxine‐pyrimethamine plus amodiaquine did not have significant lower odds of rapid diagnostic tests‐confirmed malaria than those receiving non‐sulfadoxine‐pyrimethamine plus amodiaquine (OR 0.77, 0.42–1.42). However, children receiving sulfadoxine‐pyrimethamine plus amodiaquine + amodiaquine had significantly lower odds of rapid diagnostic tests‐confirmed malaria than those receiving non‐sulfadoxine‐pyrimethamine plus amodiaquine (OR 0.42, 95% CI 0.28–0.63). Similarly, children receiving sulfadoxine‐pyrimethamine plus amodiaquine + amodiaquine + amodiaquine also had significantly lower odds of rapid diagnostic test‐confirmed malaria than those receiving non‐sulfadoxine‐pyrimethamine plus amodiaquine (OR 0.54, 95% CI 0.47–0.62).

Conclusion

Adherence to at least one daily dose of amodiaquine administration following receipt of Day 1 sulfadoxine‐pyrimethamine plus amodiaquine by eligible children is crucial to ensure the effectiveness of seasonal malaria chemoprevention. This demonstrates the importance of enhancing caregiver awareness regarding the importance of amodiaquine and identifying barriers toward amodiaquine administration at the community level.